Glycominds receives MS blood test approval in 3 more US states

Pennsylvania, Maryland, and Rhode Island approved the tests, bringing the total number of state approvals to 48.

Blood sugar analysis company Glycominds Ltd. (TASE: GLCM) has obtained marketing approval of its multiple sclerosis blood test from three more state regulatory authorities - Pennsylvania, Maryland, and Rhode Island - bringing the total number of approvals to 48. The two holdouts are New York and Florida. The company plans to submit separate applications for the device to the relevant authorities by the end of the year.

Glyclominds says that 21% of multiple sclerosis patients in the US live in these five states. The company's California laboratory has obtained regulatory approval for high complexity testing for immunology and chemistry.

Glycominds has obtained marketing approval for its gMS Dx early diagnosis test for multiple sclerosis and its gMS Pro EDSS test for diagnosing multiple sclerosis deterioration. The company's third multiple sclerosis test - gMS Pro CDMS for predicting clinical attacks in early-stage multiple sclerosis patients - has successfully completed a clinical trial.

Glycominds added that it is steadily increasing US sales of its blood tests. Sales in June alone equaled sales for the whole of the first quarter.

Glycominds' share price rose 2.6% in morning trading to NIS 1.06, giving a market cap of NIS 37 million.

Published by Globes [online], Israel business news - - on July 10, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018